Differential actions of aclarubicin and doxorubicin: The role of topoisomerase I

Oncology Research

Volumn 9, Issue 10, 1997, Pages 535-542

  Bridewell, David J A ^a   Finlay, Graeme J ^a   Baguley, Bruce C ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Cancer Research Laboratory   (New Zealand)

Author keywords

Camptothecin; Cell cycle; Doxorubicin; Topoisomerase I

Indexed keywords

ACLARUBICIN; ANTINEOPLASTIC ANTIBIOTIC; CROSS LINKING REAGENT; DNA TOPOISOMERASE; DOXORUBICIN;

ARTICLE; CELL CULTURE; CELL DIVISION; CELL FREE SYSTEM; COMPARATIVE STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; PHYSIOLOGY; WESTERN BLOTTING;

ACLARUBICIN; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL DIVISION; CELL-FREE SYSTEM; CROSS-LINKING REAGENTS; DNA TOPOISOMERASES, TYPE I; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; TUMOR CELLS, CULTURED;

EID: 0031305020     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Brown, J. R. New natural, semisynthetic and synthetic anthracycline drugs. In: Neidle, S.; Waring, M. J., eds. Molecular aspects of anti-cancer drug action, 1st ed. London: Macmillan; 1983:57-92.
2. Weiss, R. B.; Sarosy, G.; Clagett-Carr, K.; Russo, M.; Leyland-Jones, B. Anthracycline analogues: Past, present and future. Cancer Chemother. Pharmacol. 18:185-197; 1986.
3. Di Marco, A. Adriamycin (NSC-123127): Mode and mechanism of action. Cancer. Chemother. Rep. 6:91-106; 1975.
4. DuVernay, V. H., Jr.; Pachter, J. A.; Crooke, S. T. Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure-activity relationships of marcellomycin and its analogues as compared to adriamycin. Biochemistry 18:4024-4030; 1979.
5. Wang, J. C. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta 909:1-9; 1987.
6. Tewey, K. M.; Rowe, T. C.; Yang, I.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian topoisomerase II. Science 226:466-468; 1984.
7. Capranico, G.; Supino, R.; Binaschi, M.; Capolongo, L.; Grandi, M.; Suarato, A.; Zunino, F. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol. 45:908-915; 1994.
8. Unverferth, D. V.; Magorien, R. D.; Leier, C. V.; Balcerzak, S. P. Doxorubicin cardiotoxicity. Cancer Treat. Rev. 9:149-164; 1982.
9. Natale, R. B.; Cody, R. L.; Simon, M. S.; Wheeler, R. H. An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: A novel approach to the study of analogs. Cancer Chemother. Pharmacol. 31:485-488; 1993.
10. Jensen, P. B.; Larsen, S. K.; Stilbo, I. Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer. Cancer Chemother. Pharmacol. 30:219-220; 1992.
11. Jensen, P. B.; Sorensen, B. S.; Demant, E. J.; Sehested, M.; Jensen, P. S.; Vindelov, L.; Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res. 50:3311-3316; 1990.
12. Beck, W. T.; Kim, R.; Chen, M. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Cancer Chemother. Pharmacol. 34:S14-S18; 1994.
13. Sehested, M.; Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol. 51:879-886; 1996.
14. Jensen, P. B.; Jensen, P. S.; Demant, E. J. F.; Friche, E.; Sorensen, B. S.; Sehested, M.; Wassermann, K.; Vindelov, L.; Westergaard, O.; Hansen, H. H. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells - relationship to DNA integrity and topoisomerase-II. Cancer Res. 31:5093-5099; 1991.
15. Sorensen, B. S.; Jensen, P. B.; Sehested, M.; Jensen, P. S.; Kjeldsen, E.; Nielsen, O. F.; Alsner, J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: Role of topoisomerase I. Biochem. Pharmacol. 47:2105-2110; 1994.
16. Wassermann, K.; Markovits, J.; Jaxel, C.; Capranico, G.; Kohn, K. W.; Pommier, Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol. 38:38-45; 1990.
17. Haldane, A.; Finlay, G. J.; Gavin, J. B.; Baguley, B. C. Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother. Pharmacol. 29:475-479; 1992.
18. Finlay, G. J.; Baguley, B. C.; Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 139:272-277; 1984.
19. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1990.
20. Holdaway, K. M.; Finlay, G. J.; Baguley, B. C. Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines. Eur. J. Cancer 28A:1427-1431; 1992.
21. Zhitkovich, A.; Costa, M. A simple, sensitive assay to detect DNA-protein crosslinks in intact cells and in vivo. Carcinogenesis 13:1485-1489; 1992.
22. Costa, M.; Zhitkovich, A.; Taioli, E.; Toniolo, P. Preliminary report on a simple new assay for DNA-protein crosslinks as a biomarker of exposures experienced by welders. J. Toxicol. Environ. Health 40:217-222; 1993.
23. Finlay, G. J.; Baguley, B. C.; Snow, K.; Judd, W. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J. Natl. Cancer Inst. 82:662-667; 1990.
24. Snow, K.; Judd, W. Characterisation of adriamycin-resistant and amsacrine-resistant human leukaemic T-cell lines. Br. J. Cancer 63:17-28; 1991.
25. Jensen, P. B.; Sorensen, B. S.; Sehested, M.; Demant, E. J. F.; Kjeldsen, E.; Friche, E.; Hansen, H. H. Different modes of anthracycline interaction with topoisomerase-II-separate structures critical for DNA-cleavage, and for overcoming topoisomerase-II-related drug resistance. Biochem. Pharmacol. 45:2025-2035; 1993.
26. Sullivan, D. M.; Glisson, B. S.; Hodges, P. K.; Smallwood-Kentro, S.; Ross, W. E. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 25:2248-2256; 1986.
27. Rowe, T.; Kupfer, G.; Ross, W. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem. Pharmacol. 34:2483-2487; 1985.
28. Finlay, G. J.; Wilson, W. R.; Baguley, B. C. Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase !!-directed drugs. Eur. J. Cancer Clin. Oncol. 25:1695-1701; 1989.
29. Barcelo, F.; Martorell, J.; Gavilanes, F.; Gonzalez-Ros, J. M. Equilibrium binding of daunomycin and adriamycin to calf thymus DNA. Temperature and ionic strength dependence of thermodynamic parameters. Biochem. Pharmacol. 37:2133-2138; 1988.
30. Chen, A. Y.; Yu, C.; Bodley, A.; Peng, L. F.; Liu, L. F. A new mammalian DNA topoisomerase-I poison Hoechst-33342-cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53:1332-1337; 1993.
31. Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 49:5969-5978; 1989.
32. Yang, D. Z.; Wang, A. H. J. Structure by NMR of antitumor drugs aclacinomycin A and B complexed to d(CGTACG). Biochemistry 33:6595-6604; 1994.
33. Dong, J.; Naito, M.; Tatsuta, T.; Seimiya, H.; Johdo, O.; Tsuruo, T. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant p388 cell lines. Oncol. Res. 7:245-252; 1995.
34. Wolverton, J. S.; Danks, M. K.; Granzen, B.; Beck, W. T. DNA topoisomerase-II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase-II inhibitors. Cancer Res. 52:4248-4253; 1992.
35. Chen, M.; Beck, W. T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase-II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 53:5946-5953; 1993.
36. Finlay, G. J.; Holdaway, K. M.; Baguley, B. C. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemother. Pharmacol. 34:159-165; 1994.
37. Chatterjee, S.; Cheng, M. F.; Berger, S. J.; Berger, N. A. Induction of M(r) 78,000 glucose-regulated stress protein in poly(adenosine diphosphate-ribose) polymerase- and nicotinamide adenine dinucleotide-deficient V79 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide. Cancer Res. 54:4405-4411; 1994.
38. Yun, J.; Tomida, A.; Nagata, K.; Tsuruo, T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol. Res. 7:583-590; 1995.
39. Finlay, G. J.; Baguley, B. C. Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur. J. Cancer Clin. Oncol. 25:271-277; 1989.
40. Glisson, B.; Gupta, R.; Hodges, P.; Ross, W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: Evidence for a common intracellular target. Cancer Res. 46:1939-1942; 1986.
41. Barlogie, B.; Drewinko, B.; Johnston, D. A.; Freireich, E. J. The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Res. 36:1975-1979; 1976.
42. Haldane, A.; Holdaway, K. M.; Finlay, G. J.; Baguley, B. C. Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. Cancer Chemother. Pharmacol. 32:463-470; 1993.
43. Perez, C.; Campayo, L.; Navarro, P.; Garciabermejo, L.; Aller, P. The action of the DNA intercalating agents 4′-(9-acridinylamino) methanesulphon-m-anisidide and 1,4-bis-(butylamino) benzo[g]phthalazine in U-937 human promonocytic cells: Relationship between cell cycle and differentiation. Biochem. Pharmacol. 48:75-82; 1994.
44. Riou, J. F.; Fosse, P.; Nguyen, C. H.; Larsen, A. K.; Bissery, M. C.; Grondard, L.; Saucier, J. M.; Bisagni, E.; Lavelle, F. Intoplicine (RP-60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase-I and topoisomerase-II activities. Cancer Res. 53:5987-5993; 1993.
45. Finlay, G. J.; Riou, J.-F.; Baguley, B. C. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine 4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer. 32A:708-714; 1996.